+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID04422912

Safety and Dosing Study of Autologous CART Cells DSG3-CAART and CABA-201 for Active Pemphigus Vulgaris

Led by Cabaletta Bio · Updated on 2026-10-15

40

Participants Needed

13

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and appropriate dosing of special immune cells called autologous CART cells, specifically DSG3-CAART and CABA-201, in adults with active pemphigus vulgaris PV, a painful autoimmune disease causing blisters on skin and mucous membranes. This phase 12 open-label trial includes patients with mucosal and mucocutaneous forms of PV, focusing on those not well controlled by standard treatments. Participants receive either DSG3-CAART through single or multiple intravenous infusions at different dose levels, or CABA-201 as a single intravenous infusion, sometimes combined with preconditioning treatments like cyclophosphamide and fludarabine. The DSG3-CAART part of the study is no longer enrolling, while the CABA-201 sub-study is ongoing. These treatments are being evaluated for safety and how they affect the disease. During the trial, participants undergo various assessments including monitoring for adverse events up to three months for DSG3-CAART and up to 28 days or longer for CABA-201. Researchers track immune cell levels, autoantibody changes, disease activity scores, clinical remission status, and other biomarkers for up to 36 months or longer. The study includes regular evaluations to understand the treatment effects and safety over time.

CONDITIONS

Brief Title

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Research Team

C

Cabaletta Bio

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here